Literature DB >> 3497434

HIV infection in a defined population of Swedish haemophiliacs.

S Schulman, G Biberfeld, M Blombäck, B Böttiger, N Egberg, H Johnsson, B Wiechel.   

Abstract

The results of a clinical follow-up of 124 Swedish patients with haemophilia A and B or severe form of von Willebrand's disease are reported, especially with regard to HIV infection and complications thereof. 44 of the patients were anti-HIV positive. In this group there was an increasing prevalence of lymphadenopathy (18 cases), diarrhoea and fungal infections. 10 patients had generalized persistent lymphadenopathy. Platelet counts were significantly lower and IgG, IgA and IgM levels significantly higher than in the anti-HIV negative group. Oligoclonal protein bands in the gammaglobulin region were found in 8 of the anti-HIV positive patients. The vast majority of these changes have appeared during the past year, and 1-5 years after seroconversion. Presently 22/44 (50%) anti-HIV positive haemophiliacs have at least one symptom related to this infection. Most of the clinical complications have been possible to treat or to mitigate so far.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3497434     DOI: 10.3109/00365548709032393

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  3 in total

Review 1.  The clinical prognosis of HIV-1 infection: a review of 32 follow-up studies.

Authors:  G S Cooper; D J Jeffers
Journal:  J Gen Intern Med       Date:  1988 Nov-Dec       Impact factor: 5.128

2.  Incidence of symptoms and AIDS in 146 Swedish haemophiliacs and blood transfusion recipients infected with human immunodeficiency virus.

Authors:  J Giesecke; G Scalia-Tomba; O Berglund; E Berntorp; S Schulman; L Stigendal
Journal:  BMJ       Date:  1988-07-09

3.  Immunoglobulin levels in haemophiliacs at HIV seroconversion and during follow up.

Authors:  M Blombäck; H Kjellman; S Schulman; N Egberg; B Böttiger; B Wiechel
Journal:  Infection       Date:  1987 Jul-Aug       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.